Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Donna S. Neuberg, D.Sc.

Co-Author

This page shows the publications co-authored by Donna Neuberg and Benjamin Ebert.
Connection Strength

3.363
  1. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021 08 10; 5(15):2982-2986.
    View in: PubMed
    Score: 0.238
  2. ZBTB33 is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing. Blood Cancer Discov. 2021 09; 2(5):500-517.
    View in: PubMed
    Score: 0.237
  3. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019 08 09; 365(6453):599-604.
    View in: PubMed
    Score: 0.207
  4. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018 04 11; 10(436).
    View in: PubMed
    Score: 0.189
  5. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017 07 13; 377(2):111-121.
    View in: PubMed
    Score: 0.179
  6. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017 02 09; 376(6):536-547.
    View in: PubMed
    Score: 0.174
  7. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
    View in: PubMed
    Score: 0.173
  8. Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. Blood. 2015 Jun 04; 125(23):3668-9.
    View in: PubMed
    Score: 0.155
  9. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
    View in: PubMed
    Score: 0.151
  10. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 Dec 25; 371(26):2488-98.
    View in: PubMed
    Score: 0.150
  11. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 Oct 23; 124(17):2705-12.
    View in: PubMed
    Score: 0.148
  12. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
    View in: PubMed
    Score: 0.146
  13. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012 Sep 20; 30(27):3376-82.
    View in: PubMed
    Score: 0.127
  14. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011 Jun 30; 364(26):2496-506.
    View in: PubMed
    Score: 0.118
  15. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood. 2011 Aug 25; 118(8):2296-304.
    View in: PubMed
    Score: 0.117
  16. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood. 2022 01 20; 139(3):357-368.
    View in: PubMed
    Score: 0.061
  17. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2021 May; 27(5):927.
    View in: PubMed
    Score: 0.058
  18. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2021 Mar; 27(3):562.
    View in: PubMed
    Score: 0.058
  19. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020 10; 26(10):1549-1556.
    View in: PubMed
    Score: 0.055
  20. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020 07 09; 136(2):157-170.
    View in: PubMed
    Score: 0.055
  21. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
    View in: PubMed
    Score: 0.055
  22. Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. Am J Hematol. 2020 03; 95(3):245-250.
    View in: PubMed
    Score: 0.053
  23. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell. 2019 02 11; 35(2):283-296.e5.
    View in: PubMed
    Score: 0.050
  24. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019 07; 33(7):1747-1758.
    View in: PubMed
    Score: 0.050
  25. CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. Cancer Discov. 2018 07; 8(7):884-897.
    View in: PubMed
    Score: 0.048
  26. Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica. 2018 04; 103(4):626-633.
    View in: PubMed
    Score: 0.046
  27. NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. Am J Hematol. 2017 Jul; 92(7):E123-E124.
    View in: PubMed
    Score: 0.044
  28. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
    View in: PubMed
    Score: 0.042
  29. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
    View in: PubMed
    Score: 0.041
  30. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014 Mar 24; 5:3469.
    View in: PubMed
    Score: 0.036
  31. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013 Sep; 27(9):1832-40.
    View in: PubMed
    Score: 0.034
  32. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia. 2013 Oct; 27(10):2077-81.
    View in: PubMed
    Score: 0.034
  33. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. 2013 Nov; 27(11):2177-86.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.